CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
Y-T Tai(Dana-Farber Cancer Institute), Yosef Landesman(Karyopharm Therapeutics (United States)), Chirag Acharya(Dana-Farber Cancer Institute), Yolanda Calle(King's College London), Mike Zhong(Dana-Farber Cancer Institute), Michele Cea(Dana-Farber Cancer Institute), Daniel Tannenbaum(Dana-Farber Cancer Institute), Antonia Cagnetta(Dana-Farber Cancer Institute), Michaela R. Reagan(Dana-Farber Cancer Institute), Aditya Munshi(Dana-Farber Cancer Institute), William Senapedis(Karyopharm Therapeutics (United States)), J-R Saint-Martin(Karyopharm Therapeutics (United States)), Trinayan Kashyap(Karyopharm Therapeutics (United States)), Sharon Shacham(Karyopharm Therapeutics (United States)), Michael Kauffman(Karyopharm Therapeutics (United States)), Yumei Gu(University of Florida Health), Lizi Wu(University of Florida Health), Irene M. Ghobrial(Dana-Farber Cancer Institute), Fenghuang Zhan(University of Iowa), Andrew L. Kung(University of Iowa), Stephen Schey(Dana-Farber Cancer Institute), Paul G. Richardson(Dana-Farber Cancer Institute), Nikhil C. Munshi(Dana-Farber Cancer Institute), Kenneth C. Anderson(Dana-Farber Cancer Institute)
Cited by 308Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis